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Abstract
Chlamydia trachomatis (Ct) is the leading sexually transmitted infection (STI) across Eu-
rope. In Italy, Ct prevalence is low in general population, but predominance of asymp-
tomatic infections, passive voluntary reporting, variable diagnostic criteria and coding 
practices can lead to considerable underestimation, preventing assessment of real bur-
den of disease and health intervention. We analysed data on female genital Ct infection 
registered in STI sentinel surveillance systems in Italy from 2005 through 2016 and found 
3305 women. Among them, those aged 20-24 years had the highest disability-adjusted 
life years (DALYs) estimation equal to 106.77 DALYs per 100 000-stratum specific pop-
ulation. Through the study period, incidence rate (IR) for female Ct infection increased 
significantly from 2.9 to 7.1 per 100 000 resident population. Besides, we analysed data 
on pelvic inflammatory disease (PID) reported from the National Hospital Information 
system (NHIS) in the same period. We found 287 women hospitalised with concurrent 
PID and Ct infection. We recommend targeted screening programmes in women aged 
20-24, definition of nationwide active surveillance system, standardisation of diagnostic 
criteria and ICD-9CM coding practices.
INTRODUCTION 
Genital infection caused by Chlamydia trachomatis 
(Ct) is the most commonly reported sexually trans-
mitted infection (STI) across Europe [1]. In 2012, the 
World Health Organization (WHO) estimated 131 mil-
lion new annual infections among people aged 15-49 
years [2]. 
Ct infection is curable by antibiotic treatment and 
long-term protective immunity is not induced [3]. As-
ymptomatic Ct genital infection is estimated in about 
70% of women [2], therefore it is often undiagnosed or 
untreated, favouring a silent spread of infection. Other-
wise, short-term acute symptoms of cervicitis arise. In-
fection can ascend to the upper reproductive tract and 
cause long-term sequelae as chronic pelvic pain, pelvic 
inflammatory disease (PID), tubal factor infertility 
(TFI) and ectopic pregnancy [2]. Recently, a systematic 
literature review conducted by the European Centre for 
Disease Prevention and Control (ECDC) estimated a 
4-19% risk of developing PID after Ct infection. The 
risk for chronic pelvic pain after PID was estimated 
around 18-75%. Infertility was associated to 16% of the 
women with PID in reproductive age [4]. 
European (EU) population-based analyses reported 
that prevalence of female Ct infection ranged between 
1.7% and 17% [5, 6]. In 2004, the burden of Ct infec-
tion and associated sequelae estimated in terms of dis-
ability-adjusted life years (DALYs) metric ranked third 
(0.2 million DALYs including both sexes) in the WHO 
EU Region behind tuberculosis and HIV/AIDS (1.7 
and 1.2 million DALYs, respectively) [7].
In Italy, Ct infection notification is not mandatory, 
national epidemiological data in the general popula-
tion are not available, and neither national guidelines 
on who should be tested nor Ct screening programmes 
exist. Different sources of epidemiological data have 
been used to describe the dynamics of Ct infection in 
Italy, including: a) the STI Sentinel Surveillance System 
(SSS) based on a network of clinics (SSS-STIClin) [8]; 
b) the STI-SSS based on a network of microbiology lab-
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oratories (SSS-STILab) [8]; c) local studies conducted 
among specific population groups (e.g., young women, 
pregnant women) [9-17]. Singly, these data-sources do 
not provide nationwide estimate on the number of Ct 
infections and associated sequelae. So far, lack of na-
tional burden on Ct genital infection has not allowed 
drawing specific health promotion policies or educa-
tional programmes for primary prevention. 
The objective of the present study is to analyse the 
trend of Ct genital infection among women (outpa-
tients or hospitalised cases) in Italy. The above data-
sources are evaluated together for the first time to 
provide estimates on the national burden of female Ct 
genital infection and its sequelae in terms of DALYs.  
MATERIALS AND METHODS      
Study design
We performed a retrospective ecological study by 
analysing three data-sources (SSS-STIClin, SSS-STI-
Lab, and the National Hospital Information System – 
NHIS) to describe temporal trends of female Ct genital 
infection reported in Italy in the period 2005-2016 and 
to calculate its burden by DALYs metrics. We estimated 
the number of women who experienced severe Ct-asso-
ciated sequela as those hospitalised with PID caused by 
Ct genital infection. As PID can have several causes, as 
a proxy, we identified the women hospitalised with PID 
and concurrent Ct infection. Due to country-specific 
issues on disease coding and consequent possible un-
derestimation of data, we included Ct diagnosis at any 
body site among those hospitalised. For both Ct and 
PID cases, we considered women aged 15-70 years.
Data-sources and case definitions
• SSS-STIClin: the network is composed of 12 public 
STI clinics located in 11 cities (Gorizia, Trento, Bres-
cia with two clinics, Milan, Turin, Genoa, Bologna, 
Florence, Rome, Bari, Cagliari) distributed in 10 
out of 21 Italian regions and autonomous provinces. 
These specialised clinics provide diagnosis, treatment 
and care to symptomatic STI patients. Since 1991, 
this system collects anonymous individual socio-
demographic, behavioural and clinical information 
on people with a confirmed STI. Only the first STI 
episode is reported. Since 2008, the diagnosis of Ct 
infection has been performed on endo-cervical swab 
and/or the first void urine by nucleic acid amplifica-
tion test (NAAT). Previously, immune-enzymatic 
or immunofluorescence methods and swab samples 
were used. For the present analysis, we included 
women with Ct-related genital symptoms and labora-
tory-confirmed diagnosis of Ct registered in the SSS-
STIClin from 2005 through 2016. 
• SSS-STILab: the network is composed of 13 public 
microbiology laboratories located in 13 cities (Trieste, 
Pordenone, Trento, Legnano, Turin, Ivrea, Fano, Pe-
rugia, Rome, Galatina, Lecce, Catanzaro, Cosenza) 
distributed in nine out of 21 Italian regions and au-
tonomous provinces. Since 2009, these laboratories 
collect anonymous individual sociodemographic, be-
havioural and clinical data on people (symptomatic 
and non-symptomatic) who undergo testing for Ct 
and/or Neisseriae gonohorroeae and/or Trichomonas vag-
inalis. For the diagnosis of Ct infection, laboratories 
perform NAAT on samples from endo-cervical swab 
and/or the first void urine. We considered women 
tested for Ct, regardless of the presence of Ct-related 
genital symptoms.
• NHIS: it has 100% national coverage including hos-
pitalised cases and day-surgery interventions of symp-
tomatic people admitted to hospital. Demographic 
and clinical data are reported in digital medical re-
cords and include up to five reasons for admission, 
which were used in the algorithms described below. 
For the present analysis, we defined a woman with Ct 
and PID by using two algorithms (one for Ct-positive 
women and one for PID cases). We based these al-
gorithms on two sets of the International Classifica-
tion of Diseases – 9th revision – Clinical Modifica-
tion (ICD-9CM) codes specific for Ct infection or 
PID (13 and 32 codes, respectively; available online 
as Supplementary Material 1). Both algorithms were 
developed with the technical advice of gynaecologists 
qualified in Ct infection, and based on international 
literature. All data were anonymised.
We obtained approval from the Ministry of Health 
(MoH) to manage and analyse data. 
Incidence rates 
The incidence rate (IR) of Ct infection was obtained 
by dividing the number of women diagnosed with Ct 
infection reported in the SSS-STIClin by the number 
of women resident in the cities where the clinics are 
located. 
We stratified the rough IR by four age groups (i.e. 
15-24, 25-34, 35-44 and 45-70) and we calculated age-
standardised IR in respect to the general Italian popula-
tion. To estimate DALYs metrics, we used age groups 
by 4-year interval, according to the BCoDE model re-
quirements (e.g. 15-19, 20-24, 25-29, and so on until 
65-69).  
The hospitalisation rates of women diagnosed with 
PID (hospPID rate) and of women diagnosed with con-
current PID and Ct infection (hospPIDCt rate) were 
obtained by dividing the number of women hospitalised 
with PID and that of women hospitalised with concur-
rent PID and Ct, respectively, by the number of women 
aged 15-70 years resident in Italy in the reference period. 
Data were stored and managed according to the Ital-
ian privacy rules. Neither informed consent, nor ethical 
committee clearance were required for this retrospec-
tive study. 
We performed descriptive statistical analysis using 
STATA version 12. Pearson – and Fisher exact tests 
were used to assess significance (p <0.05 level) in the 
trend analysis. We described the geographical distribu-
tion of cases in Northern, Central and Southern (in-
cluding islands) areas according to ISTAT criteria [18].
DALYs estimate
We estimated the burden of Ct infection in Italy in 
terms of DALYs with 95% uncertainty intervals (UI) 
by using the ECDC-funded Burden of Communicable 
Diseases in Europe (BCoDE) toolkit [19, 20]. DALYs 
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metric included the number of years of life lost due to 
disability (YLD) and the number of years of life lost due 
to premature death (YLLs). We estimated the number 
of women diagnosed with Ct in the period 2009-2016 
by multiplying the number (equal to 21 135 688) of 
Italian women aged 15-70 years in 2012 (central year in 
the reference period) with the Ct infection prevalence 
(2.6%) obtained from the SSS-STILab (data from the 
national AIDS unit – COA, unpublished data) between 
2009 and 2016. Then, we calculated the number of 
symptomatic cases by multiplying our estimated num-
ber of women diagnosed with Ct with the BCoDE tran-
sition probability (equal to 20%, the percentage of Ct 
cases that develop symptomatic infection according to 
the BCoDE toolkit [19, 20]). We estimated the median 
annual number of symptomatic women by age group 
in Italy based on the age distribution of symptomatic 
women observed summing up data from the SSS-STI-
Lab and the SSS-STIClin. We ran the BCoDE model 
by performing 10 000 iterations and null time discount 
rate. We presented results as median values and 95% 
UI, per year and per 100 000 stratum specific popula-
tion (age group or Ct acute infection or Ct-associated 
sequelae), in terms of aggregated (i.e. DALY) and dis-
aggregated (i.e. YLDs and YLLs) analysis. 
RESULTS
From 2005 through 2016, the SSS-STIClin reported 
1301 symptomatic women diagnosed with genital Ct 
(Figure 1A), Almost half (45.9%) of them were aged 
15-24 years (median age 25 years, interquartile range 
(IQR) 22-30 years) and over two thirds (70.1%) were 
Italian (data not showed). Based on these data, the 
number of women diagnosed with Ct doubled in the 
12-years considered, from 76 cases in 2005 to 188 cas-
es in 2016 (Figure 1A), accounting for 6.1% and 11.7% 
of women reported by the network with an STI, respec-
tively. IR of female Ct infection increased significantly 
from 2.9 per 100 000 residents in 2005 to 7.1 per 100 
000 residents in 2016 (p <0.0001). In particular, we 
showed a sharp increase starting from 2009 (IR 2.8 
per 100 000 residents) to 2016 (IR 7.1 per 100 000 
residents) (p <0.0001) (Figure 1A). Overall, the rough 
IR was 45.4 per 100 000 resident women. The stan-
dardised IR was 34.0 per 100 000 female population 
distributed among the four age-groups as follows: 14.9, 
11.2, 2.3 and 5.6 among the age-groups 15-24, 25-34, 
35-44, and 45-70 years, per 100 000 female popula-
tion, respectively.
From 2009 through 2016, the SSS-STILab reported 
2275 women diagnosed with genital Ct (63.6% were 
symptomatic, data not showed). Their median age was 
27 years (IQR 22-34 years) and most of them (81.3%) 
were Italian. Prevalence of female Ct infection re-
mained stable from 2.4% in 2009 to 2.6% in 2016, with 
a peak in 2014 (3.2%; p <0.05; data not showed).
In the period 2005-2016, we identified 329 880 
(0.78%) women hospitalised with PID with or without 
Ct infection among those reported in NHIS. Among 
them, 287 (0.087%) were reported with ICD-9CM 
codes (available online as Supplementary material 1) 
identifying Ct infection (Figure 1A). The median age of 
women affected by PID and Ct was 32 years (IQR 23-
38 years). The majority (72.5%) had Italian nationality 
(available online as Supplementary Material 2). 
Based on the results obtained from the BCoDE tool-
kit, the annual DALYs per 100 000 stratum specific 
population stratified by age group (Figure 1B) shows 
the burden of Ct infection affecting mostly the women 
aged 20-24 years (106.77 DALYs per 100 000 stratum 
specific population). 
In particular, the number of Ct women was estimated 
in 111 575 cases per year (Table 1). The median annual 
burden of Ct acute infection was estimated at 23.99 
DALYs (95% UI: 21.28-26.92) per year corresponding 
to 0.08 DALYs per 100 000 stratum specific popula-
tion (95% UI: 0.07-0.09). Regarding acute infection, 
DALYs were due entirely to YLDs (Table 1). 
Overall, we estimated that over 99% of the nation-
al burden of Ct infection resulted from sequelae and 
amounted to 5978.85 DALYs per year corresponding to 
19.10 DALYs per 100 000 stratum specific population 
(95% UI: 9.84-34.22; Table 1). 
As for the Ct-associated PID cases, we observed a de-
creasing temporal trend from 27 average cases in 2005-
2006 to 17 average cases in 2015-2016, although not 
significant in terms of hospPIDCt rate (0.093 in 2005 
and 0.069 in 2016 per 100 000 residents; p >0.05). 
Figure 2A shows the Ct-associated PID cases stratified 
by year of notification and Italian and non-Italian na-
tionality. Figure 2B shows that the highest hospPIDCt 
rate (0.24 per 100 000 residents) was among the wom-
en aged 15-24 years. During the 12-year period, most 
(41.8%) of the hospitalised foreign women diagnosed 
with concurrent PID and Ct were between 25 and 
34 years old, while the majority of the Italian women 
(33.2%) were admitted to hospital with PID and Ct 
later in lifetime, at between 35 and 44 years old (Figure 
2B). Mainly, hospitalised women diagnosed with con-
current PID and Ct were reported and resided in North 
Italy (66.6% and 63.8%, respectively) and had median 
hospital stay of five days (available online as Supple-
mentary material 2). Almost half of them (43.6%) were 
admitted to the hospital under emergency conditions: 
23.7% had a scheduled admission, 18.1% had a doctor’s 
proposal and 1.4% were transferred from other public 
or private institutes; 13.2% had non-specified type of 
provenance (data not showed). 
Based on the results obtained from the BCoDE tool-
kit, PID resulted as the main sequela of Ct infection, 
together with chronic pelvic pain syndrome (Table 1). 
Overall, the annual burden of Ct-associated sequelae 
was estimated at 5954.85 DALYs (95% UI: 3057.00-10 
686.03). It was almost completely (99.8%) due to YLD 
and corresponded to 19.03 DALYs per 100 000 stratum 
specific population (95% UI: 9.77-34.14; Table 1).
DISCUSSION    
Here we described cases due to Ct genital infection 
reported in Italy from 2005 through 2016 in SSS-STI-
Clin and from 2009 through 2016 in SSS-STILab, and 
we estimated the national burden of female Ct infec-
tion in terms of DALYs metrics. Besides, we calculated 
the incidence of a severe sequela as Ct-associated PID 
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requiring hospitalisation registered in NHIS between 
2005 and 2016. Although female Ct genital infections 
(adding up both SSS-STIClin and SSS-STILab data) 
significantly increased by 26% between 2009 and 2016, 
in this period the number of hospitalised women with 
PID and Ct infection has halved, even if not significant-
ly. These diverse temporal trends might be explained by 
a range of events: I) rise in the number of Ct symptom-
atic cases; II) improved sensitivity in their notification 
among STI clinics, mostly due to increased sensitivity of 
NAAT testing after 2008; III) potential increase in test-
ing rates; IV) earlier detection of genital Ct infection 
allowing timely treatment and prevention of sequelae 
[21]; V) shift in PID care from inpatient to outpatient 
settings based on comparable reproductive outcomes 
among women with mild-to-moderate PID to contain 
costs [22, 23]; VI) lack of standardised diagnostic cri-
teria to define PID cases in hospital medical records 
leading to low accuracy in ICD-9CM coding and un-
derestimation of Ct-associated PID cases. An overall 
decline in the hospitalisation rates for PID was reported 
also in other countries [1, 24]. 
The reliability of the information obtained from our 
data-sources, the national coverage of NHIS, the stable 
collection of data over time and the high diagnostic 
standards for Ct infection adopted in the clinics and 
microbiology laboratories participating in the sentinel 
systems make this study worthy. Underestimation of 
cases with Ct genital infection limited our analysis. In 
fact, Ct infection is not reported mandatorily in Italy, 
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Figure 1
Temporal trends and rates of women affected by Chlamydia trachomatis (Ct) genital infection and pelvic inflammatory disease 
(PID) occurred in Italy, 2005-2016 (A), and burden of Ct (B) expressed in disability-adjusted life years (DALYs).
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Table 1
Annual estimated burden of Chlamydia trachomatis female infection and associated sequelae, Italy, 2009-2016 (time discounting 
was not applied). We obtained data from the Burden of Communicable Diseases in Europe (BCoDE) toolkit funded by the European 
Centre for Disease Prevention and Control (ECDC)
Cases per Year DALY per 
case
per 100 000 
Stratum specific population
YLD YLL DALY YLD YLL DALY
Acute total 111 575.01 23.99 0 23.99 2.15E-04 0.08 0 0.08
Sequelae
Pelvic inflammatory disease 60 234.11 395.30 0 395.30 3.54E-03 1.26 0 1.26
Tubal infertility 122.47 14.93 0 14.93 1.34E-04 0.05 0 0.05
Ectopic pregnancy 428.81a 10.61 8.79 19.40 1.74E-04 0.03 0.03 0.06
Chronic pelvic pain syndrome 27 919.23 5523.73 0 5523.73 0.05 17.65 0 17.65
Tubo-ovarian abscess 481.87 1.49 0 1.49 1.34E-05 4.77E-03 0 4.77E-03
Sequelae Total 5 946.07 8.79 5 954.85 0.05 19.00 0.03 19.03
All health outcomes Total 5 970.06 8.79 5 978.85 0.05 19.07 0.03 19.10
aIncluded 0.16 death. Abbreviations: DALYs, disability-adjusted life years; YLD, years lived with disability; YLL, years of life lost due to premature death. The toolkit is 
freely downloadable from https://ecdc.europa.eu/en/publications-data/toolkit-application-calculate-dalys. Results are expressed in median values. 
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Figure 2
Distribution of women diagnosed with pelvic inflammatory disease and Chlamydia trachomatis notified to the NHIS by nationality 
and year of hospitalisation (A) or age group (B), with cumulative Incidence Rate, Italy 2005-2016.
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the SSS-STILab collected data by those laboratories 
participating in the network only and the SSS-STIClin 
reported symptomatic patients who attended these 
public clinics. We have no track of those tested at other 
public clinics and laboratories, or at private health care 
facilities. Besides, frequent absence of symptoms and/
or lack of awareness to be infected by Ct lead to under-
ascertainment of cases from the community. In addi-
tion, women diagnosed with PID approaching health 
care in Italy receive syndromic management and are not 
hospitalised. In case of persistence of symptoms only, 
after 48h they might be hospitalised with diagnosis of 
possible PID due to polymicrobial genital infection 
(without laboratory confirmation). Regional differences 
in ICD-9CM coding accuracy and ability for Ct diag-
nosis might explain different proportions of hospital-
ised cases in diverse Italian areas.
Taking into account that 9-15% of women diagnosed 
with PID are hospitalised [4] and based on the num-
ber of hospitalised PID cases observed in our 12-year 
analysis, about 2-3 million women with PID due to all 
causes were expected in Italy during 2005-2016. Con-
sidering that 4%-19% of PID cases are estimated to be 
associated with Ct infection [4], in the reference period 
about 88 000-700 000 PID cases due to Ct infection 
(up to about 60 000 cases per year) were expected. 
We found correspondence between this estimate on 
the number of PID cases caused by Ct and the results 
obtained with the BCoDE toolkit. Of them, based on 
the above-mentioned 9-15% PID hospitalization rate, 
8000-100 000 women with PID due to Ct infection 
should have been hospitalised in the period 2005-2016. 
We identified 287 hospitalised women diagnosed with 
concurrent PID and Ct infection. This result suggests 
that in Italy under-reporting might play a relevant role 
in this discrepancy and at the same time that Ct-asso-
ciated PID cases are hospitalised rarely and treated at 
home mostly, anyway increasing the rates of antibiotic 
consumption needed for the therapy, if not the costs of 
hospitalization.
Moreover, we showed that Ct infection affected 
mostly young women aged 15-24 years, and that the 
contribution of young non-Italian women in the spread 
of Ct infection is considerable (about one-third among 
the 15-24 age group), confirming data reported by the 
SSS-STILab [8, 17]. 
Under ascertainment, changes in testing practices 
and case definitions together with voluntary reporting 
suggested the need for improving and standardising the 
clinic-diagnostic path and data collection for Ct genital 
infections and associated sequelae. National prevention 
strategy for STI has been absent since 2012 [25]. As of 
January 14, 2019, as little as 68 dedicated public health-
care services for Ct diagnosis and case management ex-
ist throughout the country (over 60 million residents) 
[26]. A small number compared to other EU countries 
with similar population [25]. The diagnostic test for Ct 
is offered free of charge in some clinics only. Currently, 
sexual health and STI prevention are optional part of 
school education and specific Ct prevention campaigns 
have never be delivered. 
CONCLUSIONS 
We recommend the establishment of nationwide ac-
tive surveillance system of laboratory-confirmed cases 
of Ct genital infection to monitoring the type of diag-
nostic tests used and evaluating assay-dependant differ-
ences of Ct incidence and prevalence in diverse settings 
and geographical areas through the country. Quality 
and focused epidemiological studies could better char-
acterise risky sexual behaviours of the population most 
at risk to address targeted educational programmes 
for primary prevention. Promotion of condom use at 
the community level should be implemented. Overall, 
our national estimate for female Ct infection exceeded 
twice the EU burden (19.10 DALYs and 8.52 DALYs 
per 100 000 stratum specific population, respectively) 
[27], evidencing urgent need to starting preventive pro-
grammes to diagnose early and treat properly Ct infec-
tion, thus avoiding sequelae. Indeed, one single offer 
of Ct screening may reduce the incidence of PID at 1 
year by 36% [4]. Our results pointed to young women 
between 20 and 24 years old as the population with the 
highest DALYs. Age targeted screening programmes 
with educational interventions would allow timely treat-
ment by capturing adolescents usually reluctant to seek 
medical care, also identifying those asymptomatic who 
otherwise would not have been tested.
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